Comparative Pharmacology
Head-to-head clinical analysis: FEMLYV versus NORLESTRIN FE 2 5 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMLYV versus NORLESTRIN FE 2 5 50.
FEMLYV vs NORLESTRIN FE 2.5/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropins, inhibits ovulation, alters cervical mucus and endometrium.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) via negative feedback on the hypothalamus and pituitary. Increases cervical mucus viscosity to impede sperm penetration and induces endometrial atrophy to prevent implantation.
FEMLYV (norethindrone acetate/ethinyl estradiol) is administered as one tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets. The dosing regimen is continuous cyclic.
One tablet orally once daily, each containing 2.5 mg norethindrone acetate and 50 mcg ethinyl estradiol, plus 7 iron tablets (75 mg ferrous fumarate) taken during the placebo week.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours, supporting once-daily dosing in most patients.
Norethindrone: ~8-10 hours (terminal), requiring daily dosing for stable contraceptive effect. Ethinyl estradiol: ~13-21 hours (terminal), supporting once-daily administration.
Primarily renal (approximately 60-70% as metabolites, less than 10% as unchanged drug); fecal excretion accounts for about 20-30%.
Norethindrone: ~80% renal (as glucuronide and sulfate conjugates), ~20% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal, with enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive